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Optimization of protein loaded PLGA nanoparticles manufacturing 
parameters following a quality-by-design approach  
V. Sainza,b, C. Peresa, T. Cimana, C. Rodriguesa, A. S. Vianac, C. A. M. Afonsoa, T. Baratab, S. 
Brocchinib, M. Zlohd, R. S. Gaspara, H. F. Florindoa and J. A. Lopesa* 
Development of a multivariate-based regression model for estimating the critical attributes for establishing a design-space 
for poly(lactic-co-glycolic acid) (PLGA) nanoparticles formulated by a double emulsion-solvent evaporation method. Three-
level, full factorial experimental design to assess the impact of three different manufacturing conditions (polymer viscosity, 
surfactant concentration and amount of model antigen ovalbumin) on five critical particle attributes (zeta potential, 
polydispersity index, hydrodynamic diameter, loading capacity and entrapment efficiency). The optimized formulation was 
achieved with a viscosity of 0.6 dl/g, surfactant concentration of 11 % (w/v) in the internal phase and 2.5 % (w/w) of 
ovalbumin. The design-space that is satisfied for nanoparticles with the targeted attributes was obtained with a polymer 
viscosity between 0.4 and 0.9 dl/g, surfactant concentration ranging from 8 to 15 % (w/v) and 2.5 % (w/w) of ovalbumin. 
The nanoparticles were spherical and homogenous and were extensively taken up by JAWS II murine immature dendritic 
cells without affecting the viability of these phagocytic cells. Better understanding was achieved by multivariate regression 
to control process manufacturing to optimize PLGA nanoparticle formulation. Utilization of multivariate regression with a 
defined control space is a good tool to meet product specifications, particularly over a narrow variation range.   
 
Introduction 
Nanotechnology has become increasingly important during the 
last two decades, especially in biomedical and health sciences, 
where it is used for the prevention, diagnosis and treatment of 
disease.1 Much effort is focused on producing nanosystems to 
protect loaded pharmaceutically active molecules from 
systemic degradation and to target specific tissues and cells. It 
thus becomes possible to achieve higher therapeutic levels at 
lower doses, thus reducing off-target toxicity profiles. 
Submissions of nanomedicines to the regulatory agencies have 
also increased as more has become known about these complex 
medicines.2 However, from 1994 to 2013 there was an average 
of only two nanomedicines accepted per year by the European 
Medicines Agency (EMA), mostly due to late stage clinical trial 
failures.3, 4 
 
Nanomedicines are often considered to be complicated systems 
compared to traditional medicines. The manufacture of 
nanomedicines is acutely reliant on process optimization. Raw 
materials and multiple process factors influence their 
physicochemical properties that then impact biological 
performance.2, 5 Unfortunately, most nanomedicines are 
developed empirically without any deep understanding of 
process-property relations, and not taking into account the 
challenges for scaling the production process of the best 
candidates.5-8 The scale-up of laboratory developed processes 
for nanomedicine fabrication is complex as minor variations 
often cause loss of stability and reduce biological activity.2 
While early collaboration between academia and the 
pharmaceutical industry is important,9 it becomes more and 
more important to investigate the process-nanomedicine 
relationships at preclinical stages fastening the clinical 
development.  
For all these reasons, the US Food and Drug Administration 
(FDA) recommends the use of the Quality by Design (QbD) 
approach for the rational design of nanomedicines to preserve 
drug product quality.2 QbD is one of today’s critical topics 
concerning new pharmaceuticals manufacturing process 
development, as described in the International Conference on 
Harmonization guideline Q8 (R2)-Pharmaceutical.10 QbD 
involves defining critical quality attributes (CQAs) of 
pharmaceuticals and critical process parameters (CPPs) 
together with the establishment of relations between these 
properties aiming at defining a range within the CPPs space 
leading to drug product specifications compliance. Drug 
product specifications are based on the desired efficacy and 
safety (drug performance) characteristics and will be part of a 
aResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, 
Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal 
bSchool of Pharmacy University College of London, WC1N 1AX London, United 
Kingdom 
cChemistry and Biochemistry Center, Sciences Faculty, Universidade de Lisboa, 
1749-016 Lisbon, Portugal 
dUniversity of Hertforshire, AL10 9AB Hertfordshire, United Kingdom 
 
ARTICLE Journal Name 
2 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx 
Please do not adjust margins 
Please do not adjust margins 
risk-based quality control strategy. The CPPs optimal region is 
called the design-space.11 A common methodology for 
understanding the relationships between CPPs and CQA 
explores design of experiments (DoE) strategies coupled with 
multivariate data analysis methods. 12 
The DoE approach to conduct experiments minimizes the 
workload and amount of required materials, due to the 
simultaneous variation of several factors and consequent 
evaluation of their combined effect on CQAs.13 DoE has been 
applied in the formulation optimization of different 
nanosystems, including metallic,14, 15 lipid,16, 17 and polymeric 
nanoparticles.18, 19 
Poly(lactic-co-glycolic acid) (PLGA) is one of the most explored 
biocompatible and biodegradable synthetic polymer for the 
delivery of multiple bioactive molecules, being a component of 
medicines already approved by FDA and EMA for parenteral 
administration in humans.20 This is the most studied biomaterial 
for drug delivery, presenting particularly attractive mechanical 
properties and tunable degradation rates, suitable for the 
release of the desired dose and release interval of hydrophilic 
and hydrophobic molecules.21 However, the manufacturing 
process of PLGA nanoparticles on a current good manufacturing 
practice (GMP) compliant environment is not easy or 
economically attractive. In fact, several laboratory steps 
typically used for making PLGA nanoparticles (e.g. 
ultracentrifugation or sonication) cannot be easily scaled-up.20 
Additionally, encapsulation of proteins in PLGA nanoparticles is 
often problematic especially when the most used water-in-oil-
in-water (w/o/w) double emulsion-solvent evaporation 
procedure is adopted.22 
This work explores the development of a multivariate 
regression model for estimating CQAs of PLGA nanoparticles for 
vaccine delivery prepared by the double emulsion-solvent 
evaporation method,23 aiming at defining a design-space. The 
adopted methodology relies on a DoE for the evaluation of the 
impact of different product-related manufacturing conditions 
(polymer viscosity (PolVisc), surfactant concentration (PVA) and 
amount of model antigen ovalbumin (OVA)) on zeta potential 
(ZP), polydispersity index (PdI), hydrodynamic diameter (Z-ave), 
loading capacity (LC) and entrapment efficiency (EE).  
To the best of our knowledge this is the first time that this set 
of CPPs (PolVisc, PVA and OVA) was evaluated applying a QbD 
approach for the manufacturing of nanoparticles. In the 
literature, studies describing DoE approaches to control 
manufacturing processes of polymeric nanosystems are in fact 
in limited number, and only a few of those established a design-
space. Moreover, the use of DoE software in this context has 
been reported only once by Choisnard et al. (2005) to control 
the size of amphiphilic cyclodextrin nanoparticles.24 
Results and Discussion 
Models  
Models were fitted considering experiments produced according to 
the DoE (Table 1).  
 
Table 1 Experimental design table and experimental results. 
Exp. 
Factors Responses 
PVA 
(%) 
PolVisc 
(dl/g) 
OVA 
(%) 
Z-ave 
(nm) 
PdI ZP 
(mV) 
EE 
(%) 
LC 
(µg/mg) 
1 5.0 1.0 0.0 239.9 0.109 -2.17 0.000 0.000 
2 5.0 1.0 2.5 233.0 0.188 -3.06 76.72 19.18 
3 5.0 1.0 5.0 204.3 0.103 -2.88 47.49 23.74 
4 10 1.0 0.0 212.5 0.079 -3.35 0.000 0.000 
5 10 1.0 2.5 210.7 0.141 -2.71 56.09 14.02 
6 10 1.0 5.0 206.5 0.086 -2.72 49.97 24.98 
7 15 1.0 0.0 228.2 0.079 -2.90 0.000 0.000 
8 15 1.0 2.5 216.3 0.096 -2.95 45.83 11.46 
9 15 1.0 5.0 207.2 0.062 -3.94 49.50 24.75 
10 5.0 0.2 0.0 210.8 0.192 -2.74 0.000 0.000 
11 5.0 0.2 2.5 214.2 0.177 -2.66 86.62 21.65 
12 5.0 0.2 5.0 187.9 0.076 -4.24 51.33 12.83 
13 10 0.2 0.0 224.6 0.213 -3.07 0.000 0.000 
14 10 0.2 2.5 191.6 0.158 -3.11 83.63 20.91 
15 10 0.2 2.5 191.9 0.110 -2.73 88.38 22.10 
16 10 0.2 2.5 192.9 0.107 -3.80 85.42 21.36 
17 10 0.2 2.5 198.9 0.106 -2.88 49.01 12.25 
18 10 0.2 5.0 191.4 0.153 -4.24 56.35 14.09 
19 15 0.2 0.0 210.5 0.175 -3.44 0.000 0.000 
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20 15 0.2 2.5 209.2 0.177 -2.94 39.42 9.860 
21 15 0.2 5.0 * * * * * 
22 5.0 0.6 0.0 209 0.061 -2.29 0.000 0.000 
23 5.0 0.6 2.5 196.7 0.043 -3.38 83.44 20.86 
24 5.0 0.6 5.0 196.8 0.125 -2.9 12.96 3.240 
25 10 0.6 0.0 194.6 0.055 -2.39 0.000 0.000 
26 10 0.6 2.5 197.2 0.086 -3.73 37.35 9.340 
27 10 0.6 5.0 191.5 0.057 -3.05 33.67 8.420 
28 15 0.6 0.0 189.5 0.070 -2.54 0.000 0.000 
29 15 0.6 2.5 203.8 0.115 -1.07 35.62 8.900 
30 15 0.6 5.0 188.1 0.103 -2.58 19.43 4.860 
*Results not shown since this experiment was excluded from the analysis. 
Before any modeling attempt, data from all experiments were 
subjected to an outlier test to avoid unwanted effect of incoherent 
experiments in models. Principal components analysis (PCA) is a 
recommended method for the detection of outliers on multivariate 
data.25 Data from the 30 experiments were modeled by PCA (auto-
scaled data) and three principal components were retained 
encompassing 91.8 % of the total data variance. Both Hotelling’s T2 
and squared prediction error statistics signalled experiment 21 as an 
outlier, as the factors used in this experiment (15 % (w/v) PVA, 0.2 
dl/g PolVisc, 5 % (w/w) OVA) lead to unstable nanoparticles.  In 
consequence, this experiment was excluded from further processing. 
All models considered initially a structure encompassing single, 
interactions and squared terms. Each response model was pruned by 
excluding statistically non-significant terms considering a significance 
level of 0.05. Terms were removed one-by-one sequentially until no 
statistically non-significant terms were present or until a reduction 
on the regression Q2 was observed (Table 2). 
 
Table 2 Models’ coefficients* and performance indicators. 
Coefficients Z-ave 
(nm) 
PdI ZP 
(mV) 
EE (%) LC 
(g/mg) 
Offset 191.9 0.080 -2.660 63.96 15.52 
PVA -2.560 --- --- -20.99 -3.240 
PolVisc 7.520 -0.020 0.160 --- -1.880 
OVA -8.450 --- -0.290 -23.94 -2.230 
PVA2 6.640 --- --- --- --- 
PolVisc2 13.75 0.050 -0.470 --- --- 
PVA*OVA --- --- --- 20.42 --- 
PolVisc*OVA --- --- --- --- 9.180 
Regression 
p-value 
<0.001 0.001 0.043 0.004 0.086 
RMSE 7.2 0.036 0.540 14.90 5.180 
RER 7.2 4.700 5.800 5.100 4.200 
*All coefficients are statistically significant for a significance level of 
0.05. 
 
Presented model coefficients were scaled back to original units. The 
interpretation of the non-dimensional RER parameter normally 
considers that values above 10 are indications of models with very 
good accuracy, while values between 5 and 10 are acceptable 
models, and below 5 are considered models with poor accuracy. 
Results demonstrate that most models yielded RER values between 
5 and 10, which is an indication that average accurate models were 
obtained. Note that all regressions are statistically significant at a 
significance level of 0.05 (p-values below 0.05), except the regression 
for LC with a p-value of 0.086. This was in fact the lowest RER value 
that was obtained for this attribute. The lack-of-fit test for all models 
revealed a p-value above 0.05 indicating good reproducibility (data 
not shown).  
The obtained PLGA nanoparticles’ Z-ave ranged from 187.9 to 239.9 
nm. Model for this attribute involved all single terms, together with 
squared terms for PVA (positive) and PolVisc (positive). The effects 
of PolVisc and OVA can be observed on the contour plot of Figure 1A, 
showing that a minimum nanoparticles’ Z-ave (185 nm) can be 
achieved using a PolVis in the interval 0.3 to 0.6 dl/g, for values 
ranging from 4.2 to 5.0 % (w/w) of OVA. A PLGA polymer with 
viscosity outside this range in addition to a lower OVA leads to higher 
Z-ave values. 
Yerlikaya et al. (2013) also studied the effect of surfactant 
concentration in aqueous phase (%) on Z-ave, ZP and EE of paclitaxel-
loaded PLGA nanoparticles.26 The authors also followed a QbD 
approach, but an incomplete factorial design was employed 
(Plackett-Burman design and Box-Behnke design).26 Regarding Z-ave 
response, the surfactant concentration on aqueous phase was 
considered one of the most significant factors affecting this QCA 
(pvalue = 0.026, Plackett-Burman).26 In our Z-ave model, PVA was not 
the most important factor (pvalue = 0.21), but it was observed that 
an increase in PVA in the internal aqueous phase, decreased PLGA 
nanoparticles Z-ave.  This fact was also observed by Rahman et al. 
(2010) and it was indeed expected due to the higher emulsifier 
activity that prevents droplets’ coalescence.27, 28 
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Figure 1 Contour plot showing the influence of OVA and PolVisc on 
A) Z-ave and B) ZP (simulation considering PVA=10 %).   
In our study, the square of PVA (pvalue = 0.045) was statistically more 
significant than simply the PVA factor. However, it is not possible to 
compare with Yerlikaya’s work, because Plackett-Burman design is 
not intended to evaluate factors’ interaction. In our study, the 
PolVisc was the factor that had major influence on the Z-ave 
response (pvalue = 0.0005). This may be related with the higher 
viscosity of the organic phase that could have reduced the sonication 
efficiency. According to Rahman et al. (2010) higher Z-ave was 
obtained with an increase in polymer concentration,28 due to the 
influence of higher organic phase viscosity on the shearing efficiency 
of the stirrer.28 
 
Nanoparticles manufacturing process analysis 
Z-ave is a crucial attribute governing acceptance or rejection of a 
particular nanoparticle batch. It is therefore of upmost importance 
to control this attribute over the manufacturing process. In the 
present study, Z-ave was controlled at three different stages by DLS 
(Zetasizer® Nano ZS, Malvern Instruments, UK). Accordingly, the Z-
ave for a test batch (10 % (w/v) PVA, 0.2 dl/g PolVisc, 2.5 % (w/w) 
OVA) was 190.7 nm after sonication, 176.7 nm after addition of the 
w/o/w emulsion dropwise to 0.25 % (w/w) poly(vinyl alcohol) 
external phase; finally, the suspension of solid PLGA showed a Z-ave 
of 188.2 nm at the end of the manufacturing process, after the 
centrifugation and washing steps. Therefore, the Z-ave of the final 
product of nanoparticles with this specific composition (10 % PVA, 
0.2 dl/g PolVisc, 2.5 % (w/w) OVA) was similar to the Z-ave obtained 
for the emulsion droplets in process. As a result, during the 
development process of PLGA nanoparticles by the double emulsion 
solvent evaporation techniques, the Z-ave can be accurately 
controlled through the determination of the size of the droplets of 
this emulsion. This will allow a real-time control of the size of the 
formulation, overcoming the need for an additional period of 3 hours 
to ensure solvent evaporation and particle recovery towards the 
control of the final product.   
The importance of adequately tune the manufacturing process of 
PLGA nanoparticles to achieve robustness and particles with desired 
properties was addressed by Draheim et al. (2015).13 In this study, a 
fractional factorial design was employed to plan experiments 
towards the optimisation of two distinct manufacturing processes 
(nanoprecipitation and spray-drying) used for the formulation of 
nanoparticles with the required mean particle size, size distribution 
and yield. The authors reported that the polymer concentration was 
the most important factor to control batch-to-batch variability of 
nanoparticles prepared by the nanoprecipitation process. The 
developed mathematical models based on 34 experiments, including 
repetition of 5 experiments, allowed for the prediction of both size 
and size distribution of these nanocarriers. These studies evidenced 
that higher polymer concentrations led to larger particles. On the 
other hand, the experiments evidence that the spray-drying method 
was influenced by multiple factors, being considerable difficult to 
control.  
Our manufacturing process led to a narrow particle size distribution, 
with a PdI always lower than 0.200, ranging from 0.043 to 0.213. The 
PolVisc (single and quadratic terms) was the only statistically 
significant factor retained by the model optimization process. The 
relation between PdI and the PolVisc is therefore quadratic, with a 
minimum value of particle size distribution width (0.08) obtained for 
a PolVisc of 0.6 dl/g (Error! Reference source not found.). PolVisc 
lower and higher than 0.6 dg/l increased the PdI. 
The nanoparticles shape, size and surface morphology were analysed 
by AFM. The nanoparticles had a spherical shape (Figure 3A), 
homogenous size distribution and hydrodynamic diameter lower to 
the one obtained by DLS (Figure 3C) (AFM: 166 ± 45 nm, DLS: 195 ± 4 
nm), and evidencing surface roughness (Figure 3B). Silva et. al (2014) 
obtained a similar trend in nanoparticles size.29 However, surface 
roughness herein evidenced by these optimized PLGA-based 
nanoparticles, may be due to the absence of PEG chains, in contrast 
to the smooth surface presented by OVA-loaded PEGylated 
PLGA/PCL nanoparticles described in Silva et al. (2014) previous 
work.29 
Figure 2 Main effect plot showing the influence of PolVisc on the PdI.  
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Figure 3  Nanoparticles surface morphology by AFM (715x715 nm2). 
Topography (A), Phase (B) and nanoparticles diameter (C). Mean 
diameters were calculated from 50 individual nanoparticles from 
section analysis of three different areas. 
 
The ZP of the PLGA nanoparticles was close to neutrality in all 
experiments, ranging from -4.24 to -1.07 mV. Modeling these data 
yielded a model structure involving two factors: PolVisc (single and 
quadratic terms) and OVA (single term). The model for ZP indicates 
that the highest value for surface charge (-2.4 mV) occurred when 
PolVisc was between 0.6 and 0.8 dl/g, coupled with a low OVA (Figure 
1B). PolVisc lower and higher than this range, combined with higher 
OVA, generated a decrease in the nanoparticles’ ZP. 
According to ZP response, Yerlikaya et al. (2013) considered the 
surfactant concentration an important factor (pvalue = 0.208, 
Plackett-Burman).26 In our study, the factor PVA was not statistically 
significant (pvalue = 0.88). On the other hand, OVA was considered 
the factor (pvalue = 0.05) that had the highest impact on the ZP of 
PLGA nanoparticles. This may be due to the adsorption of ovalbumin 
at the surface of the nanoparticles, due to its negative charge at 
solvent pH. This fact is supported by Verma et al. (2009) that showed 
a more negative ZP for indomethacin particles in the presence of 
Dowfax 2A1, a negatively charged stabilizer, due to its adsorption 
onto nanoparticle surface.30  
Experimental values for EE ranged from 12.96 % to 88.38 %. 
Modeling this attribute revealed that within the experimental 
conditions adopted, the EE was governed by both PVA and OVA 
(single and interaction terms). Within the tested factors’ range, 
higher PVA in the internal phase plus higher OVA led to lower EE 
(Error! Reference source not found.). Regarding EE response, 
Yerlikaya et al. (2013) also considered the surfactant concentration 
in the aqueous phase as an important factor that influences this QCA 
(our pvalue = 0.0070; pvalue = 0.205, Blackett-Burman).26 In our 
study, an increase in the PVA decreased the EE. This was also 
observed by Rahman et al. (2010) and may be attributed to the 
higher ovalbumin partitioning into the external phase.27, 28 
 
Figure 4  Contour plot showing the influence of OVA and PVA on the 
EE (simulation considering PolVisc=0.6dl/g). 
 
 
Figure 5 Contour plot showing the influence of PVA and PolVisc on 
the LC (simulation considering OVA=2.5 %). 
Experimental data for LC ranged from 3.24 to 24.98 µg/mg for 
formulations prepared following the DoE conditions. All factors are 
included in the model and appear to have an antagonistic effect on 
LC (Error! Reference source not found.). In addition to the single 
terms, an interaction term between the PolVisc and OVA was found 
to be significant. If a value of 2.5 % (w/w) is considered for OVA, the 
influence of PolVisc and PVA on LC was easily identified, as shown in 
Error! Reference source not found.. The LC decreases when the 
PolVisc increases. An inverse pattern was observed for PVA, where 
lower values led to higher LC. 
Different proteins and peptides have been explored as antigens 
associated to PLGA nanoparticles as potential vaccine candidates. 
Besides ovalbumin, bovine serum albumin (BSA) and ovalbumin class 
I and class II epitopes are among the most explored ones.31-34 The 
molecular weight and isoelectric point of proteins can indeed 
influence the nanoparticle physicochemical properties, namely the 
LC and Z-ave. However, multiple reports indicate that the double 
emulsion solvent evaporation technique used in the formulation of 
these nanoparticulate vaccines is a versatile but robust 
methodology, allowing for the successful development of 
nanoparticulate carriers presenting similar mean diameters and LC 
for proteins of different physical and chemical properties, such as 
ovalbumin and BSA, but also small peptides.35 We have previously 
demonstrated that the Z-ave, PdI, ZP and LC of PLGA-based 
nanoparticles was not affected by the molecular weight of entrapped 
antigens, namely ovalbumin or the peptides Melan-A:26-35(L27), 
gp100:209-217(2 M) or gp100:44-59.36 Therefore, one can expect 
similar factors to be considered when defining the experimental 
design. 
The FTIR analysis allows the assessment of the chemical 
composition of Ovalbumin-associated PLGA nanoparticles, providing 
data regarding the nature of protein-polymer interactions and thus 
the compatibility between the protein and polymeric components of 
these carriers. The FTIR spectra profiles obtained for both PLGA 
nanoparticle and ovalbumin-loaded PLGA nanoparticles are similar 
to the one obtained for the PLGA polymer (Figure 6). It is evident a 
strong stretching absorption at 1740-1770 cm−1, which indicates the 
presence of the carboxylic group (C=O bond). In addition, there are 
no visible changes in the position of the typical peaks of the 
ovalbumin in the FTIR of spectrum ovalbumin-loaded PLGA 
nanoparticles and no shift can also be identified for the O-H 
stretching (3200-3500 cm−1) of the PLGA polymer.37-39 In fact, the 
specific bands of the functional groups of the polymer in the 
nanoparticle are not different from those visible in the pure material. 
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Therefore, the molecular interactions that could be established 
between the polymer and the protein and alter the chemical 
structure of the protein did not occur. As a result, it can be expected 
an adequate protection of the entrapped ovalbumin by the 
polymeric matrix.    
 
Figure 6 FTIR spectra of PLGA nanoparticles and formulation 
components. Band at 1740-1770 cm−1 is specific for the carboxylic 
group (C=O bond), while 3200-3500 cm−1 corresponds to the O-H 
groups. 
 
 
Models’ Validation 
To validate models, an additional experiment was conducted. This 
experiment was defined as using factor levels able to generate a 
nanoparticle with optimal attributes, hereby designed by 
specifications. These specifications were defined according to target 
values of the five attributes recognized as suitable for the optimal 
delivery and capture of extensive amounts of antigens to APCs. The 
Z-ave should be between 190.0 and 220.0 nm, because this size 
range enables high EE and LC levels, and enables nanoparticle 
delivery through the lymphatic system.40 Similarly, low PdI values 
(between 0.1 and 0.15) should be obtained, evidencing 
homogeneous and stable formulation samples with no aggregates. 
The ZP should be close to neutrality (between -4 and 4 mV) as neutral 
surface charged nanoparticles are less cytotoxic than charged ones, 
being also less captured and therefore metabolized by the non-
specific first line of defence. The EE and LC levels should be the 
highest to enable the maximum content inside the nanoparticles.  
Specifications were then set to values of EE ranging from 90.0 to 99.0 
%, and 24.0 to 25.0 µg/mg for LC. The set of factors able to generate 
a nanoparticle with these characteristics was estimated by running 
the optimizer feature in MODDE. Target values comprising a range of 
minimum and maximum values (tolerance for the optimizer) were 
set. The optimizer predicted a formulation with the following factors: 
PVA= 11 % (w/v), PolVisc= 0.6 dg/l and OVA= 2.5 % (w/w). This 
experiment was conducted and experimental values for the five 
responses were compared to models’ predictions (Table 3).  
Table 3 Target formulation specifications and models’ validation for 
a nanoparticle formulated with PVA=11%, PolVisc=0.6dl/g and 
OVA=2.5%. 
*Experimentally determined value within the model’s predicted 
interval 
 
The experimental values for these nanoparticles were globally well 
predicted by the five models. Moreover, the average value for each 
attribute was within the model’s 95 % prediction limits, except for 
PdI and EE, where the experimental values were outside, but 
considerably close to predicted lower limits. These results clearly 
confirm the prediction ability of the developed models, and 
corroborate the higher prediction accuracy of the models presenting 
higher RER and lower RMSE statistics. These results might indicate 
that within the tested factors’ range, probably some relationships are 
more complex, thus not being well predicted by these relatively 
simple linear models with interaction and quadratic terms. A non-
linear modelling strategy could unveil this hypothesis, although at an 
expense of a greater number of experiments and a tighter models’ 
validation.41 On the other hand, one should not exclude the 
possibility that other non-voluntary uncontrolled factors can affect 
the experiments outcome. Therefore, a combination of these two 
possibilities should be explored in the future towards a more robust 
identification of the factors-responses relationship allowing more 
accurate models and thus with more applicability in practice. 
 
Design Space 
A design-space was estimated from the three factors (PolVisc, PVA 
and OVA). The developed models for the five attributes supported 
the proposing design-space (Figure 7). To estimate the design-space 
boundary, a risk of failure limit of 1000 DPMO was considered. 
Accordingly, the acceptable region that fulfill those targeted features 
is achieved when 2.5 % (w/w) OVA are entrapped within 
nanoparticles. The manufacturing process should use a PolVisc 
ranging from 0.4 to 0.9 dl/g and a PVA between 8 and 15 % (w/v) to 
ensure that the attributes remain within the specifications.  
 
 
 
 
 
 
 
 
 
 
Specification Minimum 
allowed 
Target Maximum 
allowed 
Experimental Model Prediction 
Z-ave (nm) --- 190.0 220.0 189.30.778 191.76.95* 
PdI --- 0.1 0.15 0.0440.027 0.0790.026 
ZP (mV) -4.0 0 4.0 -2.280.424 -2.660.4* 
EE (%) --- 90.0 99.0 45.620.622 59.7610.57 
LC (g/mg) --- 24.0 25.0 11.400.156 14.873.925* 
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 Figure 7 Design-space for a formulation with properties as shown in 
Table III, represented in terms of the variation of PolVisc and PVA 
while considering a constant value for OVA (2.5 %). The design-space 
was built considering a risk of failure (DPMO) limit of 1000. 
 
Interaction of optimized nanoparticles with targeted cells 
 
Dendritic cell viability in the presence of nanoparticles 
In order to evaluate the effect of PLGA nanoparticles on the viability 
of JAW SII murine immature dendritic cells, an Alamar Blue® assay 
was performed (Figure 8). The assay did not evidence a negative 
impact of PLGA nanoparticles on the viability of the tested cells. The 
cell viability was close to 100 % for all the concentrations of 
nanoparticles, after 24 h of incubation (data not presented). 
Moreover, no significant differences were observed even after 48 h 
of incubation with 1000 μg/mL of nanoparticles. A similar profile was 
achieved by Silva et al. (2014) with cell viabilities were higher than 
70 % after 48 h of incubation of PLGA nanoparticles with JAWSII 
cells.29 These results show that the manufacturing process led to 
nanoparticles which residual amounts of organic solvent and 
surfactant do not affect the viability of targeted cells. In fact, the lack 
of biocompatibility has been previously reported for PVA,42 and the 
use of organic solvents is pointed as one of the major disadvantages 
for the preparation of vaccine carriers by emulsion evaporation 
methods.43 Our data is in line with our previous study in which poly-
ε-caprolactone-based vaccine carriers prepared by solvent emulsion 
evaporation method presented a residual value for DCM lower than 
the one accepted by regulation authorities, and did not affect the 
viability of BALB/c mouse monocyte macrophage J774A.1 cell line.43 
 
Figure 8 Cell viability of JAWSII murine immature dendritic cells in the 
presence of PLGA nanoparticles. Mean ± SD; N = 3, n = 6, where N 
stands for number of independent experiments and n stands for 
number of measurements per experiment. One-way ANOVA and 
Tukey’s Post Hoc test were used to compare cell viability in the four 
different nanoparticle concentrations; *p < 0.001 (relation to Triton 
X-100). 
Uptake study of nanoparticles  
 
Figure 9 Internalization profile of nanoparticles by JAW SII cells after 
3 h, 24 h and 48 h of incubation, expressed by percentage of positive 
cells in the sorted population by flow cytometry.  Mean ± SD; N = 2, 
n = 3, where N stands for the number of independent experiments 
and n stands for the number of measurements per experiment. One-
way ANOVA and Tukey’s Post Hoc test were used to compare uptake 
at any time point to 3-h incubation: *p < 0.01 and **p < 0.001. 
In order to analyse if the nanoplatforms could be internalized by 
JAWSII murine immature dendritic cells, flow cytometry studies were 
carried out. The nanoparticles were extensively internalized by the 
phagocytic cells (Figure 9). The use of Rhodamine-grafted PLGA 
polymer to obtain fluorescently-labelled nanoparticles instead of 
Rhodamine-entrapped nanoparticles is important in order to avoid 
wrong interpretations as a result of Rhodamine leakage.29  
The internalization levels increased with the incubation time (at 3 h: 
6.6 ± 2.4 FITC+ cells (%) at 3 h; 60.1 ± 4.7 % at 24 h and 79.9 ± 1.9 % 
at 48 h). Similar uptake profiles were recently reported by Silva et al. 
(2014) and Kulkarni et al. (2013).29, 44 According to Kulkarni et al. 
(2013) the cellular uptake was higher for nanoparticles in a size range 
of 100-200 nm44. The optimized nanoparticles used in this uptake 
study are within this size range. Silva et al (2014) compared the 
uptake profile of PLGA nanoparticles by immature bone marrow-
derived dendritic cells (BMDCs) and the cell line JAWSII29 by flow 
cytometry and data was confirmed by confocal microscopy. It was 
possible to observe that nanoparticles were taken up by the JAW SII 
cell line at lower extent than the primary dendritic cells, but the 
amount of nanoparticles in the interior of targeted cells increased 
with time of incubation and nanoparticle concentration.29 On the 
other hand, the uptake profile by BMDCs was totally different, being 
close to 60 % from 3h to 24 h, thus not dependent on time or even 
concentration.  
In addition of an extensive uptake of antigen-loaded PLGA 
nanoparticles by dendritic cells, the activation and effective 
maturation of these antigen presenting cells will only occur upon a 
sustained release of the antigen from the carrier. One of the major 
advantages widely recognized among the scientific community to 
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PLGA-based polymers is the possibility for adjusting their physical 
and chemical properties in order to obtain a degradation and release 
profile suited for the targeted biological effect. Properties such as 
crystallinity, glass transition temperature, solubility and molecular 
weight can have a pronounced effect on polymer physicochemical 
properties, and thus dictate payload release kinetics. PLGA 
mechanical properties and degradation rates can be adjusted 
according to the ratio and molecular weight of both monomers lactic 
and glycolic acids. The antigen release kinetics can have an important 
impact in the immune response.29, 45 PLGA degradation in buffer or 
biological fluids occurs through the hydrolytic cleavage of ester 
bonds, yielding to the accumulation of both lactic and glycolic acids. 
Even if the mechanisms of release are not completely understood, it 
is reported that it is initially driven by diffusion, while 
degradation/erosion is accepted to be the major factor at the end of 
the release process.46, 47 The latter is highly dictated by the PLGA 
molecular weight and end-group caps.48, 49 It was also demonstrated 
that diffusion has a major impact in the release rate from low 
molecular weight PLGA polymers, while both diffusion and erosion 
should be considered when evaluating the degradation profile of 
those polyester polymers presenting high molecular weights.50, 51  
Tri-phasic release profile were reported to PLGA-based nano and 
microparticles, evidencing an initial burst effect, followed by a lag-
phase mostly due to the diffusion-release mechanism and finally an 
accelerate release due to the erosion of the matrix.48, 50 It is accepted 
that the initial burst release may be due to the release of protein 
adsorbed onto nanoparticle surface.  
As suggested by the reviewer, we performed a release study which 
did not evidence an initial burst release of the ovalbumin, and 
evidenced that approximately 5 % (w/w) and 13 % (w/w) of the 
antigen initially entrapped in the PLGA nanoparticles was detected 
after 1 and 3 weeks of incubation. This data is in line with the 
expected degradation time for the PLGA polymer used for the 
formulation of nanoparticles, which can range from 4-5 months.46, 52 
As a result, we can expect a sustained release of the antigen from the 
nanoparticles developed, which is of particular importance for the 
development of a long lasting immune response.     
 
Experimental 
Materials 
PLGA Resomer® RG 755s, 752s and 750s (lactide:glycolide molar 
ratio 75:25, with inherent viscosities of 0.6, 0.2 and 1 dl/g, 
respectively) were purchased from Boehringer Ingelheim GmbH 
(Ingelheim, Germany). Poly(vinyl alcohol) (MW 13000-23000 
Da), ovalbumin, dichloromethane (DCM), phosphate buffered 
saline tablets, magnesium chloride, calcium chloride, 
Granulocyte-Macrophage Colony-Stimulating Factor human 
(GM-CSF) and potassium bromide (KBr) were supplied by Sigma-
Aldrich (St. Louis, MO, USA). RPMI 1640 Medium GlutaMAXTM 
Supplement, Fetal bovine serum (FBS), sodium pyruvate 
100mM, penicillin streptomycin, 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) solution buffer 1M, 2-
mercaptoethanol 50 mM and AlamarBlue® were purchased 
from ThermoFisher Scientific (Waltham, Massachusetts, USA). 
JAWSII murine immature dendritic cells (ATCC® CRL-11904TM) 
were obtained from American Type Culture Collection (ATCC, 
Manassas, VA, USA). Rhodamine 6G derivative (9-(2-
((carboxymethoxy)carbonyl)phenyl)-3,6-bis(ethylamino)-2,7-
dimethylxanthylium bromide) was synthesized and conjugated 
to PLGA as described elsewhere.53 
 
Preparation of PLGA nanoparticles 
 The PLGA (75/25, w/w) nanoparticles were prepared following 
a w/o/w double emulsion-solvent evaporation method 
previously developed, with specific modifications.36 Briefly, the 
PLGA polymer was dissolved in DCM and this organic phase was 
further emulsified with a poly(vinyl alcohol) solution (aqueous 
phase) at different concentrations, using a sonicator (Branson 
S-250D, 50/60 Hz, 20kHz) for 15 seconds at 20 % amplitude. 
Fluorescent nanoparticles were formulated by replacing a tenth 
of the PLGA mass by rhodamine-labelled PLGA (R-PLGA). 
Different amounts of ovalbumin, the model antigen, were 
dissolved into the aqueous phase according to the designed 
experiment. The second emulsion was formed after addition of 
1.25 % (w/v) poly(vinyl alcohol) using the conditions mentioned 
above. The double emulsion was added dropwise to 0.25 % 
(w/v) poly(vinyl alcohol) solution and stirred during 1 h at room 
temperature, allowing for solvent evaporation. The 
nanoparticles were retrieved from the suspension by 
centrifugation at 17500 rpm, 4 ºC for 45 min (Beckman Coulter 
Avanti J-E Centrifuge, JA-20 rotor). Nanoparticles were washed 
twice with purified water by centrifugation, under the same 
conditions. The pellet was resuspended in Dulbecco’s 
phosphate buffered saline (DPBS), and stored at 4 ºC until 
analysis. 
 
Experimental design 
A three level full factorial experimental design was performed 
resourcing to the software MODDE version 10.1 (MKS Umetrics, 
Sweden).54, 55 PolVisc (0.2 dl/g, 0.6 dl/g, 1 dl/g), PVA (5 % (w/v), 
10 % (w/v), 15 % (w/v)) and OVA (0 % (w/w), 2.5 % (w/w), 5 % 
(w/w)) were the varied manufacturing conditions (factors). The 
PolVisc corresponds to the PLGA inherent viscosity measured at 
25ºC, 0.1 % (w/v) in chloroform, with a size 0c Ubbelohde glass 
capillary viscometer. The PVA corresponds to the amount of 
poly(vinyl alcohol) added in the internal aqueous phase. The 
OVA corresponds to ovalbumin percentage of the used 
polymer’s mass. The Z-ave, PdI, ZP, EE and LC were the 
evaluated properties (responses). Summing to the design 27 
experiments, three replicates of the central point (to access 
model’s lack-of-fit) were performed totalizing 30 experiments 
(Table I). In addition to the DoE experiments, an additional test 
was produced using factor levels pointed-out by the developed 
mathematical models towards the production of a formulation 
with targeted specifications (see results and discussion section). 
The experiments were conducted in a random order as it is 
typically done to allow the greatest reliability and validity of 
statistical estimates. Experiment results were modelled by 
multiple linear regression and obtained models evaluated by 
analysis of variance (ANOVA). 
Nanoparticles analysis 
 
Physicochemical characterisation 
Z-ave and PdI were determined by Dynamic Light Scattering 
(DLS) (Zetasizer® Nano ZS, Malvern Instruments, UK). ZP was 
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measured by Laser Doppler Electrophoresis (Malvern 
Instruments, Worcestershire, UK). All measurements were 
performed in triplicate using nanoparticles dispersed in DPBS 
(20 mg/mL) at 25 ºC.  
 
Nanoparticles surface morphology evaluation 
The nanoparticles (PVA= 11 % (w/v), PolVisc= 0.6 dg/l and OVA= 
0 % (w/w)) size, shape and surface morphology were evaluated 
by Atomic Force Microscopy (AFM), using a Nanoscope IIIa 
Multimode AFM (Digital Instruments, Veeco).29 Nanoparticle 
were diluted to 10 mg/mL with purified water. The samples 
were added dropwise to cleaved mica at room temperature and 
dried with N2. The AFM analyses were performed at a scan rate 
of approximately 1.6 Hz, using tapping mode in air at room 
temperature with etched silicon tips (ca. 300 kHz), obtaining 
topography and phase images. 
 
Entrapment efficiency and loading capacity assessment 
The EE and LC were determined by the indirect method, 
analysing the amount of ovalbumin released in the 
supernatants by HPLC (Eqs. 1 and 2). 
 
EE(% w/w) =
ovalbumin0−ovalbuminsup
ovalbumin0
     (1) 
LC(μg/mg) =
ovalbumin0−ovalbuminsup
polymer
      (2) 
In Eq. 1, ovalbumin0 is the initial amount of ovalbumin and 
ovalbuminsup is the amount of ovalbumin in the supernatant. In 
Eq. 2, polymer is the amount of polymer. 
The determination of OVA was performed using a Beckman 
System Gold HPLC (Beckman Coulter Inc.), with a Shodex 
Protein KW-803 column (8.0 mm ID x 300 mm, 5 µm particle 
size, 300 Å pore size) at room temperature, injecting samples 
with a volume of 20 µl. The mobile phase was composed of 
sodium phosphate buffer 50 mM at pH 7.0 and sodium chloride 
0.3 M. The eluent flow rate was 1.0 mL/min, for 15 min. The 
signal was monitored at 220 nm by spectrophotometric analysis 
(Hitachi U-2001 UV-vis Spectrophotometer, USA).  
 
FTIR characterization of PLGA nanoparticles 
PLGA nanoparticles were lyophilized (Modulyo freeze-dryer 
(Edwards, Germany)) in the presence of the cryoprotectant 
sucrose (0.05 % w/w) for 18 h at an initial temperature of  -40ºC 
ºC and 0,1 mBar. Lyophilized nanoparticles and the controls 
were mixed with KBr at a concentration of 1,5% (w/w) and 
compressed into a tablet (12 mm diameter) using a manual 
tablet presser. The infrared spectra were measured at the 
transmittance mode with 30 scans and a resolution of 2.0 cm-1 
(Affinity-1 Shimadzu spectrophotometer, Japan). 
 
 
Modelling 
Multiple linear regression was used to model the five responses 
against the three factors,56 resourcing to the software MODDE 
version 10.1 (MKS Umetrics, Sweden). To model EE and LC, plain 
nanoparticles experiments were discarded since the amount of 
protein in these samples is zero (Eqs. 1 and 2). Before modelling, 
factors and responses were auto-scaled (average removal and 
division by the variance). Models’ performance was assessed by 
calculating the root mean square error (RMSE) and range error 
ratio (RER) parameters. 
 RMSE = √
∑ (Yi−Ŷi)
2n
i=1
n
         (3) 
In Eq. 3, Yi is the experimentally observed value for sample i, Ŷi 
is the model predicted value for sample i and n is the number of 
samples. 
RER =
Ymax−Ymin
RMSE
         (4) 
In Eq. 4, Ymax is the maximum value of the response, Ymin is the 
minimum value of the response. 
Models’ validation and design-space  
The optimised models were used to estimate the manufacturing 
properties ideal to attain the nanoparticle specifications 
required for optimal delivery of antigens to targeted phagocytic 
cells.21 Accordingly, these nanotechnology-based vaccines 
should present mean size diameter lower than 200 nm, 
monodisperse population (PdI ≤ 0.200) and neutral surface 
charge, in order to enhance their capture by dendritic cells, 
which are known as the most potent professional antigen-
presenting cells (APCs).21 This was achieved using the optimiser 
feature of MODDE version 10.1 (MKS Umetrics, Sweden), which 
includes a simplex algorithm for optimisation. The targeted 
specifications aforementioned were introduced in the optimiser 
and series of estimations of the three factors were proposed.  
The estimation featuring the highest determinant was selected 
for the preparation of a batch of nanoparticles, in triplicate. The 
physicochemical properties of these carriers were determined, 
as described in section 2.4. The developed models were 
validated through the comparison between predictions and 
experimental values. The estimated design-space was 
constructed around the nanoparticulate system presenting the 
targeted specifications, applying the developed models for the 
five responses with MODDE version 10.1 (MKS Umetrics, 
Sweden). The design-space was built in terms of default per 
million opportunities (DPMO). 
 
Interaction of nanoparticles with targeted cells 
 
Conditions of cell culture 
JAWSII murine immature dendritic cells were propagated in 
RPMI medium with GlutaMAX with 10 % (v/v) FBS, 1% (v/v) 
sodium pyruvate, 1 % (v/v) penicillin streptomycin, 1 % (v/v) 
HEPES buffer, 0.1 % (v/v) 2-mercaptoethanol and 0.005 % (v/v) 
GM-CSF. 
 
 
In vitro cell viability 
Cell viability of JAWSII murine immature dendritic cells in the 
presence of PLGA nanoparticles ((PVA= 11 % (w/v), PolVisc= 0.6 
dg/l and OVA= 2.5 % (w/w)) was inferred by using AlamarBlue® 
Assay. The cells (1×106) were incubated overnight at 37 ºC and 
5 % CO2 and treated with increasing concentrations of 
nanoparticles (125, 250, 500 and 1000 µg/mL) for 48h. 
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AlamarBlue® was added in an amount of 10 % (v/v) of the well 
volume and the plates were read after 3 hours of incubation (37 
ºC and 5 % CO2) with the reagent. The absorbance was 
measured at two different wavelengths: 570 and 630 nm using 
a microplate reader (Biotek, ELx800, USA). The controls used in 
the assay were PBS (negative control) and Triton X-100 0.5 % 
(v/v) (positive control). 
 
In vitro uptake study by flow cytometry 
JAWSII cells (65 000/195 µl/well) were seeded in 96-well flat 
bottom plates and incubated overnight at 37 ºC and 5 % CO2. 
The uptake of the R-PLGA nanoparticles at 0.5 mg/mL (PVA= 11 
% (w/v), PolVisc= 0.6 dg/l and OVA= 0 % (w/w)) by JAWSII 
murine immature dendritic cells was evaluated at three 
different time points: 3 h, 24 h and 48 h. Nanoparticles were 
added to the cells (0.5 mg/mL) and incubated at the conditions 
mentioned above, for the indicated periods. Cells were then 
washed twice with PBS, harvested by centrifugation (1000 rpm, 
5 min, 4ºC) and resuspended with flow cytometry buffer (PBS 
sterile buffer + 2 % (v/v) FBS). The fluorescence was analyzed at 
530 nm with excitation at 488 nm using an LSRFortessa2 
cytometer (BD Biosciences) with High Throughput Sampler 
(HTS). Untreated cells were used as control and the results were 
analyzed with FlowJo software version 9.8 for Microsoft 
(TreeStar, San Carlos, CA). 
 
Conclusions 
This study evaluated the effect of PVA, PolVisc and OVA (the 
factors) on five critical PLGA nanoparticles’ attributes ZP, PdI, Z-
ave, LC and EE (the responses) during the double emulsion 
solvent evaporation process. Experiments carried out according 
to the proposed experimental design allowed the identification 
of the major factors related with the responses. This 
identification was based on the development of linear models 
and assessment of statistical significance. All factors were found 
to be relevant to explain the variability observed on both Z-ave 
and LC. PdI variability was mainly influenced by the PolVisc. PVA 
and OVA were the major sources of variability in EE and PolVisc, 
while OVA influenced the ZP response. One of the major aims in 
PLGA nanoparticles’ production is to achieve desired values for 
the nanoparticles’ properties, while ensuring the lowest 
possible batch-to-batch variability. This paper demonstrates 
that a quality-by-design approach is applicable to estimate a 
design-space allowing the developer to understand 
relationships between CPPs and CQAs, thus being able to adjust 
critical variables according to the desired nanoparticles’ 
specifications. In the particular system explored in this work, 
the developed mathematical models were able to estimate 
actual nanoparticles’ properties with accuracy adequate for 
practical use. The mathematical models were employed to 
estimate the manufacturing conditions needed to achieve a 
formulation with optimal characteristics (PVA 11%, polymer 0.6 
dl/g and OVA 2.5%). These conditions were then tested 
experimentally and the properties of the resulting nanoparticles 
were found to be in accordance with mathematical models 
prediction (within the confidence limits). Future studies will 
investigate the advantages of modelling this system with non-
linear methods in order to further increase the models’ 
accuracy. Additionally, other possible sources of process 
variability will be explored in order to include them in the 
models.  
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